Immunotherapy

Thymus May Be Critical for Longevity and Cancer Immunotherapy Response  Harvard Medical SchoolThymic health consequences in adults  NatureLong dismissed in adult health, the thymus may be critical for longevity and cancer treatment  Medical XpressThis overlooked organ may be more vital for longevity than scientists realized  Scientific AmericanClinical briefs for Thursday, March 19  McKnight's Long-Term Care News

Thymus May Be Critical for Longevity and Cancer Immunotherapy Response  Harvard Medical SchoolThymic health consequences in adults  NatureLong dismissed in adult health, the thymus may be critical for longevity and cancer treatment  Medical XpressThis overlooked organ may be more vital for longevity than scientists realized  Scientific AmericanClinical briefs for Thursday, March 19  McKnight's Long-Term Care News

Thymic health and immunotherapy outcomes in patients with cancer  NatureThymic health consequences in adults  NatureThymus May Be Critical for Longevity and Cancer Immunotherapy Response  Harvard Medical SchoolThis overlooked organ may be more vital for longevity than scientists realized  Scientific AmericanLong dismissed in adult health, the thymus may be critical for longevity and cancer treatment  Medical Xpress

Thymic health and immunotherapy outcomes in patients with cancer  NatureThymic health consequences in adults  NatureThymus May Be Critical for Longevity and Cancer Immunotherapy Response  Harvard Medical SchoolThis overlooked organ may be more vital for longevity than scientists realized  Scientific AmericanLong dismissed in adult health, the thymus may be critical for longevity and cancer treatment  Medical Xpress

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well to immunotherapy.

Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as a universal immunotherapy for cancers that form solid tumors, including common variants such as cancers of the breast, liver, and colon.

Northwestern Medicine scientists have discovered that specialized immune cells within the glioblastoma tumor metabolize fructose to suppress immune responses and promote tumor growth, reports a study published on March 17 in the Proceedings of the National Academy of Sciences.

The collaboration’s first public sign of trouble came in the first quarter of 2025, when Astellas opted not to continue IND enabling activities it had initiated for the companies’ first collaboration target—choosing instead to prioritize their second nominated collaboration target by initiating GLP toxicology studies for the molecule. The post Astellas Scraps Up-to-$1.7B CytomX Cancer Immunotherapy Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News.

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international clinical trial, NRG-LU005, led by NRG Oncology in collaboration with the Alliance for Clinical Trials in Oncology. The results are published in the Journal of Clinical Oncology.

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies.

Cells in our immune system are best known for providing security against external invaders such as bacteria and viruses. These immune cells also guard against internal threats, including cancerous tumors.

A Common Drug May Make Cancer Immunotherapy Work Better  SciTechDailyMedication Interactions in Immunotherapy With Dr. Arabella Young: PPIs and ICI Toxicity  Docwire News

A Common Drug May Make Cancer Immunotherapy Work Better  SciTechDailyMedication Interactions in Immunotherapy With Dr. Arabella Young: PPIs and ICI Toxicity  Docwire News

Fecal microbiota transplants may enhance patients’ response to immunotherapy, but experts caution that the latest data remain proof-of-concept and far from practice-changing.

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

arXiv:2602.23488v1 Announce Type: new Abstract: We continue our study of a model for cancer treatment, constructed in Dutta et. al., 2025, by adding Virotherapy to the Chemotherapy and Immunotherapy studied there. It is a dynamical system model for the spread of cancer in healthy tissue. It allows computer experiments of various combinations of the three modalities, which cannot be performed in the laboratory or experimentally. The novelty is the addition of Virotherapy. The analysis shows that the model solutions exist, are bounded, and nonnegative on each finite time interval, thus biologically feasible. A time-stepping algorithm is constructed and implemented, and computer simulations are presented. The simulations show the development of the disease under various treatment options, including a baseline case without treatment, cases for each of the three treatments separately, and some combinations of the three treatments. These simulations indicate that combinations of treatments

Ultrasound-mediated nanobubbles improve cancer therapy by softening tumors, enhancing lipid nanoparticle distribution, and activating immune responses.

Researchers developed a CAR T technology, called DROP-CAR, that incorporates human protein components, and uses a clinically approved, non-immunosuppressive drug to remotely and reversibly switch off the CAR T cells by disrupting tumor cell binding. The post Drug-Controlled CAR T Cells May Enable Safer Immunotherapy appeared first on GEN - Genetic Engineering and Biotechnology News.

A study found that a protein made by stressed cancer cells shields lung and pancreatic tumors in mice from the immune system, and showed that an antibody targeting lipocalin 2 slowed cancer growth in mice by enabling the immune system to target tumor cells. The post Cancer Immunotherapy Improved Using Targeted Stress Protein appeared first on GEN - Genetic Engineering and Biotechnology News.

Immunotherapy – which activates the body's own immune system to kill cancer cells – has not worked well against a rare and fatal liver cancer, but a new Cornell University study finds an existing FDA-approved drug may allow the immunotherapy to fight the cancer as intended, opening the door to a potential treatment.

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

A small team at OVACell is fighting ovarian cancer with hidden viral sequences and advanced immunotherapies.

A cohort study examines whether the use of common medications was associated with worse outcomes in patients with lung cancer taking immunotherapy.

Draft guidance from NICE recommends durvalumab before and after surgery for muscle-invasive bladder cancer following phase 3 trial survival data.

Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster, benefiting patients.

Initiating cow’s milk oral immunotherapy earlier in life is safe and linked to lower reactogenicity and a milder immunologic profile.

A new study offers hope that kidney transplant patients could one day have a monthly treatment instead of multiple pills every day.

European regulators have endorsed Imfinzi as part of a perioperative treatment strategy that significantly reduces recurrence and death in early-stage gastric and gastroesophageal junction cancer.

Blocking microglial Fcγ receptors can prevent dopaminergic neuron loss in Parkinson’s disease, shows a new study. The findings reveal how microglia drive degeneration and point to immunotherapy as a potential neuroprotective strategy. The post Immunotherapy Blocking Microglial FcγR Prevents Neuron Loss in Parkinson’s Disease appeared first on GEN - Genetic Engineering and Biotechnology News.

By analyzing tissue from patients with Parkinson's disease, and animal and cellular models of the disease, a research team from the Institut de Neurociències of the UAB has shown that the main immune cells of the brain become reactive and overexpress certain receptors that promote the elimination of dopaminergic neurons, even when these neurons are still functional.

FRIDAY, Jan. 30, 2026 — An already-approved immunotherapy drug can dramatically shrink — or even eliminate — tumors associated with a rare and aggressive form of melanoma, a new clinical trial has found. About 71% of desmoplastic...

It is the first immunotherapy-based treatment recommended in Europe for advanced anal cancer.

FRIDAY, Jan. 30, 2026 — An already-approved immunotherapy drug can dramatically shrink — or even eliminate — tumors associated with a rare and aggressive form of melanoma, a new clinical trial has found.About 71% of desmoplastic melanoma patients tr...

Scientists designed an immunotherapy using an engineered antibody to destroy harmful modulated smooth muscle cells located within blood vessel walls that plays a central role in driving inflammation and plaque formation in heart arteries. The post Immunotherapy Reduces Plaque in Mouse Arteries, Suggesting Coronary Disease Intervention appeared first on GEN - Genetic Engineering and Biotechnology News.

New results from a clinical trial co-led by UCLA investigators demonstrate how treating desmoplastic melanoma, a rare and aggressive skin cancer, with immunotherapy before surgery can dramatically shrink or even eliminate tumors, sparing patients from more aggressive surgeries and preserving their quality of life.

Fecal microbiota transplants (FMT), can dramatically improve cancer treatment, suggest two groundbreaking studies published in the prestigious Nature Medicine journal.

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research reveals a hidden trick: cancer cells can package the immune-blocking protein PD-L1 into tiny particles that circulate through the body and weaken immunotherapy’s impact. Scientists in Japan discovered that a little-known protein, UBL3, controls this process—and surprisingly, common cholesterol-lowering drugs called statins can shut it down.

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why some cancer patients benefit from immunotherapy while others do not.

Metastatic urothelial carcinoma has a poor prognosis: ~50% of muscle-invasive bladder cancer progresses to metastasis, and the 5-year survival for advanced/metastatic disease is

Researchers conducted a systematic review of studies assessing the cost-effectiveness or cost-utility of adjuvant immunotherapy for treating various types of cancer.

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells directly, it targets the cells that protect them.

A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer vaccine research are converging into a new era of more precise, personalized, and effective immunotherapies, particularly when combined with other cancer treatments.

Long-term survival data further support nivolumab plus ipilimumab as first-line standard of care for patients with inoperable liver cancer.

Mnt News RSS Feed

The collaboration provides Agenus with strategic capital and committed, long-term biologics manufacturing capacity in the United States to support BOT+BAL clinical development, authorized early access pathways, and commercial supply preparation. The post Agenus Closes Strategic Immunotherapeutic Collaboration with Zydus Lifesciences appeared first on GEN - Genetic Engineering and Biotechnology News.

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial.

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the potential to overcome treatment resistance to anti-PD-1 immune checkpoint inhibitors in multiple cancer types.

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the effectiveness of cancer immunotherapy, according to a new study led by Weill Cornell Medicine and Cornell Engineering researchers.

The addition of consolidative thoracic radiotherapy to chemoimmunotherapy is associated with improved survival among patients with extensive-stage small cell lung cancer.

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the effectiveness of cancer immunotherapy, according to a new study led by Weill Cornell Medicine and Cornell Engineering researchers.

Cancer has long remained a leading cause of death worldwide and in Hong Kong, accounting for 30% of all disease-related deaths in the city in 2025. While chemotherapy remains a major treatment modality, its side effects and the risk of relapse challenges for patients.

Immunotherapy has emerged in recent years as a new cancer treatment that is gentler than traditional chemotherapy and causes milder side effects in patients. However, conventional dendritic cell (DC) immunotherapy shows inconsistent clinical outcomes, and the cell culture process remains complex and costly.

Gold nanoparticles that cluster in response to T cell enzymes can predict cancer immunotherapy success days before tumors begin to shrink.

Precision immunotherapy added to standard care and tailored to specific immune dysfunctions in sepsis improves organ dysfunction compared with placebo, a multinational phase 2 trial finds.

arXiv:2512.18387v1 Announce Type: new Abstract: Glioblastoma Multiforme (GBM) is a highly aggressive brain tumour with limited therapeutic options and poor prognosis. This study presents a mathematical framework to investigate the efficacy of immunotherapy strategies based on cytotoxic T-lymphocyte (CTL) infusion. The model couples tumour and immune dynamics through a system of partial differential equations (PDEs), incorporating cell proliferation, diffusion, and chemotactic migration in response to TGF-$\beta$, a tumour-secreted signalling molecule. A reduced ordinary differential equation (ODE) model is first analysed to derive threshold conditions for tumour eradication, identifying critical infusion levels consistent with clinical data. Numerical bifurcation analysis explores the impact of parameter variations. The full PDE model is solved using the finite element method on simplified 2D domains, followed by sensitivity analyses to quantify parameter influence on tumour mass and

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established in 2024 for TRBC1-positive tumors.

Australian researchers have discovered that the TAK1 gene helps cancer cells survive attack from the immune system, revealing a mechanism that may limit the effectiveness of immunotherapy treatments.

Engineered dendritic cells with EV‑internalizing and chimeric antigen receptors capture tumor vesicles, activate T cells, and delay melanoma growth in preclinical models, advancing next‑generation cancer immunotherapy strategies. The post Engineered Dendritic Cells Harness Tumor EVs to Boost Cancer Immunotherapy appeared first on GEN - Genetic Engineering and Biotechnology News.

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some cancers and how it could be improved for others.

Changing just one atom in a COVID-19 vaccine lipid redirects delivery from the liver to the spleen, improving tumor suppression in mice.

Exposure to antibiotics during immune checkpoint inhibitor therapy may increase the risk for immune-related cutaneous adverse events.

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack dangerous cells. Yet a full understanding of how they actually work has eluded researchers.

FRIDAY, Dec. 12, 2025 — Less might be more when it comes to immunotherapy treatment of melanoma, a new study says. Lower doses of a drug used to treat melanoma can provide better results while reducing side effects, researchers reported Dec...

FRIDAY, Dec. 12, 2025 — Less might be more when it comes to immunotherapy treatment of melanoma, a new study says.Lower doses of a drug used to treat melanoma can provide better results while reducing side effects, researchers reported Dec. 8 in t...

Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.

Flipping the standard doses of nivolumab plus ipilimumab for patients with advanced melanoma may improve survival with less toxicity, a real-world study finds.

A depigmented polymerized cat allergoid is safe and generally well tolerated in patients with cat-induced allergic rhinitis, a real-world study finds.

The regimen of ponatinib combined with blinatumomab boosts outcomes vs TKI plus chemotherapy.

TUESDAY, Dec. 9, 2025 — Cancer survival might depend on what time of day you get your treatment, a new study says.Lung cancer patients who received IV immunotherapy doses earlier in the day tended to live longer, according to results published o...

Immunotherapy for sepsis is effective when doctors tailor the treatment precisely to the patient's immune system condition.

Receiving anticancer immunotherapy earlier in the day may help individuals with cancer live longer. That's according to a study published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects.

A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common tumor type, estrogen receptor-positive or luminal breast cancer.

arXiv:2512.00599v1 Announce Type: new Abstract: In this paper, we investigate a mathematical model describing the interactions between effector cells (E), cancer cells (T), and the IL-2 compound (IL). The model considered here is a generalization, taking into account some cross-diffusion effects, of a spatial cancer immunotherapy model proposed by S. Suddin et al in 2021. These modifications allow us to describe two biologically relevant scenarios: a patient treated with Adoptive Cell Immunotherapy (ACI) and a patient not receiving any treatment/therapy. Cross-diffusion effects are particularly relevant in the interactions between tumor cells and the immune system, in fact they play a key role in immune response dynamics and cannot be neglected. We analyze the equilibrium points of the homogeneous system, along with their stability and bifurcation mechanisms. Furthermore, adopting the Turing approach for reaction-diffusion systems, we investigate the diffusion-driven instability and

Correlates of HIV-1 control after combination immunotherapy  NatureSmall study shows a promising path toward HIV cure  The Washington PostPath to HIV cure includes Seattle scientists  The Seattle TimesLong-term HIV control: Combination therapy points way to a possible cure  Medical XpressNew Trials Hint That 'Functional Cure' for HIV May Be Within Reach, Helping Some Patients Achieve Lasting Remission  Smithsonian Magazine

Correlates of HIV-1 control after combination immunotherapy  NatureSmall study shows a promising path toward HIV cure  The Washington PostPath to HIV cure includes Seattle scientists  The Seattle TimesLong-term HIV control: Combination therapy points way to a possible cure  Medical XpressNew Trials Hint That 'Functional Cure' for HIV May Be Within Reach, Helping Some Patients Achieve Lasting Remission  Smithsonian Magazine

A new study from UC San Francisco shows it may be possible to control HIV without long-term antiviral treatment - an advance that points the way toward a possible cure for a disease that affects 40 million people around the world.

Adult patients with an aggressive form of leukemia will be able to receive a breakthrough immunotherapy, which was invented by UCL researchers, on the NHS within weeks following approval for use by the National Institute for Health and Care Excellence (NICE).

For some patients with the most common type of lung cancer, known as lung adenocarcinoma, there's new hope.

Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism called "myeloid mimicry" to hide from the immune system and promote disease hyper progression after immunotherapy, highlighting specific targets that overcome treatment resistance in preclinical models.

In patients with local allergic rhinitis, allergen immunotherapy yields sustained reductions in nasal-ocular symptoms, with preventive effect on the development of asthma and allergic sensitizations.

A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in the course of treatment.

Tumors exploit TSP-1–CD47 signaling to exhaust T cells, weakening immunotherapy. Blocking this pathway restores T-cell function, slows tumor growth, and enhances response to PD-1 treatment, offering improved cancer therapies. The post New T Cell–Suppressive Pathway Highlights TSP-1–CD47 as Immunotherapy Booster appeared first on GEN - Genetic Engineering and Biotechnology News.

MONDAY, Nov. 10, 2025 — Evidence is mounting that oral immunotherapy can help many children shake off food allergies.Children benefited from being fed small amounts of food allergens to desensitize them, according to a pair of studies presented o...

arXiv:2511.05527v1 Announce Type: new Abstract: A critical need exists for optimal therapeutic strategies for neuroblastoma, a prevalent and often fatal pediatric solid malignancy. To address the demand for quantitative models that can guide clinical decision-making, a novel mathematical framework was developed. Combination therapies involving immunotherapy, such as Interleukin-2 (IL-2), and chemotherapy, exemplified by Cyclophosphamide, have shown significant clinical potential by enhancing anti-tumor immune responses. In this study, a nonlinear system of coupled ordinary differential equations was formulated to mechanistically describe the interactions among tumor cells, natural killer (NK) cells, and cytotoxic T lymphocytes (CTLs). The pharmacodynamic effects of both IL-2 and Cyclophosphamide on these key immune populations were explicitly incorporated, allowing for the simulation of tumor dynamics across distinct patient risk profiles. The resulting computational framework

Two new studies being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Orlando shine a spotlight on oral immunotherapy and oral food challenges (OFCs) in children, showing that both procedures are safe for young patients and can be life-changing for families navigating food allergies.

Using Alzheimer's mouse models, and human cells and brain tissue, scientists identified a protective role for a subset of microglia in the progression of the disease. The post Protective Microglia Identified as Potential Immunotherapy Target in Alzheimer’s appeared first on GEN - Genetic Engineering and Biotechnology News.

Down-titrating vial concentrations when restarting subcutaneous allergen immunotherapy after treatment gaps may help lower the risk for severe systemic reactions.

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators reveals how melanoma, the deadliest form of skin cancer, evolves to resist immunotherapy and identifies a potential strategy to prevent or reverse that resistance.

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two

The use of neoadjuvant immunotherapy for patients with head and neck squamous cell carcinoma has nearly doubled since 2013 in the US, but disparities in access exist.

FRIDAY, Oct. 24, 2025 — The mRNA technology powering some COVID vaccines may hold a surprising benefit for advanced cancer patients: a potential ability to "rev up" the immune system to better use immunotherapy medicines to attack t...

T cells play central roles in the adaptive immune response against cancer. Their functional inactivation is a primary driver of tumor progression, making the reactivation of T cell function a main goal in immunotherapy.

Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful therapies.